Compare UEIC & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UEIC | EDSA |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.6M | 51.5M |
| IPO Year | 1995 | 2018 |
| Metric | UEIC | EDSA |
|---|---|---|
| Price | $4.31 | $4.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.50 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 97.9K | 75.8K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $368,288,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.69 | $0.72 |
| 52 Week High | $5.99 | $20.32 |
| Indicator | UEIC | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 38.77 | 41.16 |
| Support Level | $3.87 | $4.80 |
| Resistance Level | $4.43 | $6.62 |
| Average True Range (ATR) | 0.33 | 0.63 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 4.35 | 26.67 |
Universal Electronics Inc is engaged in universal wireless control solutions for the home. The company design, develop, manufacture, ship and support climate control solutions, wireless sensor and smart home control products, home entertainment control products, technology and software solutions and audio-video (AV) accessories that are used by the world's brands in the climate control, security, home automation, home appliance, home entertainment and consumer electronics markets.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.